

Welcome to the Integrated Research Application System

IRAS Project Filter

The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications.

Please complete the questions in order. If you change the response to a question, please select 'Save' and review all the questions as your change may have affected subsequent questions.

**Please enter a short title for this project** (maximum 70 characters)  
REMAP-CAP

**1. Is your project research?**

☒ Yes ☐ No

**2. Select one category from the list below:**

- ☒ Clinical trial of an investigational medicinal product
- ☐ Clinical investigation or other study of a medical device
- ☐ Combined trial of an investigational medicinal product and an investigational medical device
- ☐ Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
- ☐ Basic science study involving procedures with human participants
- ☐ Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative methodology
- ☐ Study involving qualitative methods only
- ☐ Study limited to working with human tissue samples (or other human biological samples) and data (specific project only)
- ☐ Study limited to working with data (specific project only)
- ☐ Research tissue bank
- ☐ Research database

**If your work does not fit any of these categories, select the option below:**

☐ Other study

**2a. Is this a commercially sponsored Phase 1 or Phase 1/2a trial involving healthy volunteers?**

☐ Yes ☒ No

**2b. Will the study involve the use of any medical device without a CE Mark, or a CE marked device which has been modified or will be used outside its intended purposes?**

☐ Yes ☒ No

**2c. Please answer the following question:**

Is this trial subject to advice from the Expert Advisory Group on Clinical Trials and the Commission on Human Medicine prior to authorisation from MHRA?

☐ Yes ☒ No

**2d. Please answer the following question:**

Is this a trial of a gene therapy medicinal product?

☐ Yes ☒ No

**2e. Please answer the following question(s):**

a) Does the study involve the use of any ionising radiation?

☐ Yes ☒ No

b) Will you be taking new human tissue samples (or other human biological samples)?

☐ Yes ☒ No

c) Will you be using existing human tissue samples (or other human biological samples)?

☐ Yes ☒ No

**3. In which countries of the UK will the research sites be located?(Tick all that apply)**

- ☒ England
- ☒ Scotland
- ☒ Wales
- ☒ Northern Ireland

**3a. In which country of the UK will the lead NHS R&D office be located:**

- ☒ England
- ☐ Scotland
- ☐ Wales
- ☐ Northern Ireland
- ☐ This study does not involve the NHS

**4. Which applications do you require?**

- ☒ IRAS Form
- ☒ Medicines and Healthcare products Regulatory Agency (MHRA) – Medicines
- ☐ Confidentiality Advisory Group (CAG)
- ☐ Her Majesty's Prison and Probation Service (HMPPS)

**5. Will any research sites in this study be NHS organisations?**

☒ Yes ☐ No

**5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Collaboration for Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or Medtech and In Vitro Diagnostic Cooperative in all study sites?**

Please see information button for further details.

☐ Yes ☒ No

Please see information button for further details.

**5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN) Support and inclusion in the NIHR Clinical Research Network Portfolio?**

Please see information button for further details.

☒ Yes ☐ No

*The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies happen in the NHS e.g. by providing access to the people and facilities needed to carry out research "on the ground".*

*If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form (PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for your study.*

**6. Do you plan to include any participants who are children?**

☐ Yes ☒ No

**7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent for themselves?**

☒ Yes ☐ No

*Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.*

**8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or who are offenders supervised by the probation service in England or Wales?**

☐ Yes ☒ No

**9. Is the study or any part of it being undertaken as an educational project?**

☐ Yes ☒ No

**10. Will this research be financially supported by the United States Department of Health and Human Services or any of its divisions, agencies or programs?**

☐ Yes ☒ No

**11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project (including identification of potential participants)?**

☐ Yes ☒ No

**SUBSTANTIAL AMENDMENT FORM <sup>1</sup>**

**NOTIFICATION OF A SUBSTANTIAL AMENDMENT TO A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE EUROPEAN UNION**

*For official use:*

Date of receiving the request:	Grounds for non acceptance/negative opinion:
	Date:
Date of start of procedure:	Authorisation/ positive opinion:
	Date:
Competent authority registration number of the trial:	Withdrawal of amendment application:
Ethics committee registration number of the trial:	Date:

*To be filled in by the applicant:*

*This form is to be used both for a request to the Competent Authority for authorisation of a **substantial** amendment and to an Ethics Committee for its opinion on a **substantial** amendment. Please indicate the relevant purpose in Section A.*

**A TYPE OF NOTIFICATION**

**A.1 Member State in which the substantial amendment is being submitted:**

England

**A.2 Notification for authorisation to the competent authority:** ☒

**A.3 Notification for an opinion to the ethics committee:** ☒

*(<sup>1</sup>) Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (OJ, C82, 30.3.2010, p.1) hereinafter referred to as 'detailed guidance CT-1'.*

**B TRIAL IDENTIFICATION (When the amendment concerns more than one trial, repeat this form as necessary.)**

**B.1 Does the substantial amendment concern several trials involving the same IMP?** <sup>2</sup> ☐ Yes ☒ No

**B.2 EudraCT number:** 2015-002340-14

**B.3 Full title of the trial:** Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for community - Acquired Pneumonia (REMAP-CAP)

**B.4 Sponsor's protocol code number:**

**B.4 Sponsor's protocol version number:** v3.0

**B.4 Sponsor's protocol date:** 10/07/2019

(2) Cf. Section 3.7. of the detailed guidance CT-1

## C IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

### C.1 Sponsor

Organisation: University Medical Center Utrecht  
Contact Given name: Wilma  
Contact Family name: van Bentum-Puijk  
Address: Heidelberglaan 100 (room number STR.3.127),  
Town/city: Utrecht, The Netherlands  
Post code: 3584 CX Utrecht  
Telephone:  
Fax:  
E-mail: w.w.puijk-2@umcutrecht.nl

### C.2 Legal representative <sup>3</sup> of the sponsor in the European Union for the purpose of this trial (if different from the sponsor)

Name of organisation: University Medical Center Utrecht  
Contact Given name: Albert  
Contact Family name: Vermaas  
Address: Heidelberglaan 100, 3584 CX Utrecht, The Netherlands  
Town/city: Utrecht, The Netherlands  
Post code: 3584 CX  
Telephone:  
Fax:  
E-mail: A.M.Vermaas@umcutrecht.nl

(3) As stated in Article 19 of Directive 2001/20/EC.

## D APPLICANT IDENTIFICATION, (please tick the appropriate box)

### D1. Request for the competent authority

- D.1.1 Sponsor ☒
- D.1.2 Legal representative of the sponsor ☐
- D.1.3 Person or organisation authorised by the sponsor to make the application. ☐
- D.1.4 Complete below:

Name of organisation University Medical Center Utrecht  
Contact Given name Wilma  
Contact Family name van Bentum-Puijk  
Address Heidelberglaan 100, 3584 CX Utrecht, The  
Netherlands  
Town/city Utrecht

Post code 3584 cx  
Telephone  
Fax  
E-mail W.W.Puijk-2@umcutrecht.nl

**D2. Request for the Ethics Committee**

- D.2.1 Sponsor ☒
- D.2.2 Legal representative of the sponsor ☐
- D.2.3 Person or organisation authorised by the sponsor to make the application. ☐
- D.2.4 Investigator in charge of the application if applicable<sup>4</sup>:
- Co-ordinating investigator (for multicentre trial): ☐
  - Principal investigator (for single centre trial): ☐
- D.2.5 Complete below:

Name of organisation University Medical Center Utrecht  
Given name Wilma  
Family name van Bentum-Puijk  
Address Heidelberglaan 100, 3584 CX Utrecht, The Netherlands  
Town/city Utrecht  
Post code 3584 CX  
Telephone  
Fax  
E-mail W.W.Puijk-2@umcutrecht.nl

<sup>(4)</sup> According to national legislation.

**E SUBSTANTIAL AMENDMENT IDENTIFICATION****E.1 Sponsor's substantial amendment information for the clinical trial concerned:**

Code Number: AM10  
Version: 1.0  
Date: 2020/04/05

**E.2 Type of substantial amendment**

- E.2.1 Amendment to information in the CT application form ☐ Yes ☒ No
- E.2.2 Amendment to the protocol ☒ Yes ☐ No
- E.2.3 Amendment to other documents appended to the initial application form ☐ Yes ☒ No

If yes specify:

1. changes made to the REMAP-CAP COVID-19 Antiviral domain specific appendix v1.0 11.3.20  
updated document:  
REMAP-CAP COVID-19 Antiviral domain specific appendix v2 1.4.20

- E.2.4 Amendment to other documents or information: ☒ Yes ☐ No

If yes specify:

1. changes made to the REMAP-CAP COVID-19 Antiviral domain specific appendix v1.0 11.3.20

updated document:

REMAP-CAP COVID-19 Antiviral domain specific appendix v2 1.4.20

2. changes made to the REMAP CAP COVID-19 information sheets and consent forms to reflect the changes in the amended REMAP-CAP COVID-19 antiviral domain:

UK REMAP CAP COVID19 PIS ICF V1.2 2020.04.06 TC

UK REMAP CAP COVID19 Retro PIS ICF V1.2 2020.04.06 TC

UK REMAPCAP COVID19 PerLRIS ICF v1.2 2020.04.06 TC

E.2.5 This amendment concerns mainly urgent safety measures already implemented<sup>5</sup>: ☐ Yes ☒ NoE.2.6 This amendment is to notify a temporary halt of the trial<sup>6</sup>: ☐ Yes ☒ NoE.2.7 This amendment is to request the restart of the trial<sup>7</sup>: ☐ Yes ☒ No<sup>(5)</sup> Cf. Section 3.9. of the detailed guidance CT-1.<sup>(6)</sup> Cf. Section 3.10. of the detailed guidance CT-1<sup>(7)</sup> Cf. Section 3.10. of the detailed guidance CT-1**E.3 Reasons for the substantial amendment:**E.3.1 Changes in safety or integrity of trial subjects ☐ Yes ☒ NoE.3.2 Changes in interpretation of scientific documents/value of the trial ☐ Yes ☒ NoE.3.3 Changes in quality of IMP(s) ☐ Yes ☒ NoE.3.4 Changes in conduct or management of the trial ☒ Yes ☐ NoE.3.5 Change or addition of principal investigator(s), co-ordinating investigator ☐ Yes ☒ NoE.3.6 Change/addition of site(s) ☐ Yes ☒ NoE.3.7 Other change ☒ Yes ☐ No

E.3.7.1 If yes specify:

1. changes made to the REMAP-CAP COVID-19 Antiviral domain specific appendix v1.0 11.3.20  
updated document:

REMAP-CAP COVID-19 Antiviral domain specific appendix v2 1.4.20

2. changes made to the REMAP CAP COVID-19 information sheets and consent forms to reflect the changes in the amended REMAP-CAP COVID-19 antiviral domain:

UK REMAP CAP COVID19 PIS ICF V1.2 2020.04.06 TC

UK REMAP CAP COVID19 Retro PIS ICF V1.2 2020.04.06 TC

UK REMAPCAP COVID19 PerLRIS ICF v1.2 2020.04.06 TC

E.3.8 Other case ☐ Yes ☒ No

E.3.8.1 If yes specify:

**E.4 Information on temporary halt of trial:<sup>8</sup>**

E.4.1 Date of temporary halt

E.4.2 Recruitment has been stopped ☐ Yes ☒ NoE.4.3 Treatment has been stopped ☐ Yes ☒ No

E.4.4 Number of patients still receiving treatment at time of the temporary halt in the MS concerned by the amendment

E.4.5 Briefly describe:

Justification for a temporary halt of the trial (free text):

The proposed management of patients receiving treatment at time of the halt (*free text*):

The consequences of the temporary halt for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product (*free text*):

<sup>(8)</sup>Cf. Section 3.10. of the detailed guidance CT-1

## F DESCRIPTION OF EACH SUBSTANTIAL AMENDMENT<sup>9</sup>

Please use this section to detail each substantial amendment which is being notified. If you are notifying more than one substantial amendment, please use the "Add Amendment" button as required

### Substantial amendment 1

#### Previous and new wording:(tracked)

1. changes made to the REMAP-CAP COVID-19 Antiviral domain specific appendix v1.0 11.3.20 updated document:

REMAP-CAP COVID-19 Antiviral domain specific appendix v2 1.4.20

2. changes made to the REMAP CAP COVID-19 information sheets and consent forms to reflect the changes in the amended REMAP-CAP COVID-19 antiviral domain:

UK REMAP CAP COVID19 PIS ICF V1.2 2020.04.06 TC

UK REMAP CAP COVID19 Retro PIS ICF V1.2 2020.04.06 TC

UK REMAPCAP COVID19 PerLRIS ICF v1.2 2020.04.06 TC

#### New wording:

#### Comments/ explanation/ reasons for substantial amendment:

This substantial amendment adds an additional antiviral agent, hydroxychloroquine to the COVID anti-viral domain of the REMAP-CAP trial. We will evaluate this agent on its own and also in combination with kaletra. This drug is commonly used to treat malaria and various rheumatoid illnesses and has anti-viral effects. It is being evaluated in several other clinical trials for COVID-19. We have also updated our analytical plan to include a combined analysis of all anti-viral agents compared to the current standard of care. We made a few minor semantic changes to the information sheets to make some of the terminology more lay friendly.

Thank you for your prompt review of these changes

<sup>(9)</sup>Cf. Section 3.7.c. of the detailed guidance CT-1. The sponsor may submit this documentation on a separate sheet.

## G CHANGE OF CLINICAL TRIAL SITE(S)/INVESTIGATOR(S) IN THE MEMBER STATE CONCERNED BY THIS AMENDMENT

### Type of change:

#### G.1.1 Addition of a new site

##### G.1.1.1 Principal investigator (provide details below)

Given name

Middle name(if applicable)

Family name



Qualification  
(MD...)  
Professional  
address

### G.1.2 Removal of an existing site

#### G.1.2.1 Principal investigator (provide details below)

Given name  
Middle name(if  
applicable)  
Family name  
Qualification  
(MD...)  
Professional  
address

#### G.1.3 Change of co-ordinating investigator (provide details below of the new coordinating investigator)

Given name  
Middle name(if  
applicable)  
Family name  
Qualification  
(MD...)  
Professional  
address

G.1.3.6 Indicate the name of the previous co-ordinating investigator:

#### G.1.4 Change of principal investigator at an existing site (provide details below of the new principal investigator)

Given name  
Middle name(if  
applicable)  
Family name  
Qualification  
(MD...)  
Professional  
address

G.1.4.6 Indicate the name of the previous principal investigator:

### H CHANGE OF INSTRUCTIONS TO CA FOR FEEDBACK TO SPONSOR

#### H.1 Change of e-mail contact for feedback on application\*

#### H.2 Change to request to receive an .xml copy of CTA data

☐ Yes ☒ No

H.2.1 Do you want a .xml file copy of the CTA form data saved on EudraCT? ☐ Yes ☒ No

H.2.1.1 If yes provide the e-mail address(es) to which it should be sent (up to 5 addresses):

H.2.2 Do you want to receive this via password protected link(s)<sup>10</sup>? ☐ Yes ☒ No

If you answer no to question H.2.2 the .xml file will be transmitted by less secure e-mail link(s)

H.2.3 Do you want to stop messages to an email for which they were previously requested? ☐ Yes ☒ No

H.2.3.1 If yes provide the e-mail address(es) to which feedback should no longer be sent:

(\*This will only come into effect from the time at which the request is processed in EudraCT).

(10) This requires a EudraLink account. (See [eudract.emea.europa.eu](http://eudract.emea.europa.eu) for details)

#### I LIST OF THE DOCUMENTS APPENDED TO THE NOTIFICATION FORM (cf. Section 3.7 of detailed guidance CT-1)

Please submit only relevant documents and/or when applicable make clear references to the ones already submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).

I.1 Cover letter ☒

I.2 Extract from the amended document in accordance with Section 3.7.c. of detailed guidance CT-1 (if not contained in Part F of this form) ☐

I.3 Entire new version of the document<sup>11</sup> ☐

I.4 Supporting information ☒

I.5 Revised .xml file and copy of initial application form with amended data highlighted ☐

#### I.6 Comments on any novel aspect of the amendment if any :

This substantial amendment adds an additional antiviral agent, hydroxychloroquine to the COVID anti-viral domain of the REMAP-CAP trial. We will evaluate this agent on its own and also in combination with kaletra. This drug is commonly used to treat malaria and various rheumatoid illnesses and has anti-viral effects. It is being evaluated in several other clinical trials for COVID-19. We have also updated our analytical plan to include a combined analysis of all anti-viral agents compared to the current standard of care. We made a few minor semantic changes to the information sheets to make some of the terminology more lay friendly.

Thank you for your prompt review of these changes...

(11) Cf. Section 3.7.c. of the detailed guidance CT-1

#### J SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

Please submit only relevant documents and/or when applicable make clear references to the ones already submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).

#### J.1 I hereby confirm that/ confirm on behalf of the sponsor that (delete which is not applicable)

- The above information given on this request is correct;
- The trial will be conducted according to the protocol, national regulation and the principles of good clinical practice; and
- It is reasonable for the proposed amendment to be undertaken.

**J.2 APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY** (as stated in section D.1): ☐

J.2.1 Signature <sup>12</sup>: .....

J.2.2 Print name:

J.2.3 Date:

This section was signed electronically by MSc Wilma Van Bentum-Puijk on 06/04/2020 14:05.

Job Title/Post: sPM  
Organisation: UMC Utrecht  
Email: w.w.puijk-2@umcutrecht.nl

**J.3 APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE** (as stated in section D.2): ☐

J.3.1 Signature <sup>13</sup>: .....

J.3.2 Print name:

J.3.3 Date:

This section was signed electronically by MSc Wilma Van Bentum-Puijk on 06/04/2020 14:07.

Job Title/Post: sPM  
Organisation: UMC Utrecht  
Email: w.w.puijk-2@umcutrecht.nl

<sup>(12)</sup> On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

<sup>(13)</sup> On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.